’·è‘åŠw‘åŠw‰@ˆãŽ•–òŠw‘‡Œ¤‹†‰È •ªŽq–ò—Šw•ª–ì
publication
HOME
‹³Žöˆ¥ŽA
ƒƒ“ƒo[Ð‰î
Œ¤‹†ŠT—vEŒ¤‹†‚Ö‚Ì—U‚¢
Œ¤‹†‹ÆÑ
‹³ˆçŠˆ“®
Šw‰ïEŒ¤‹†‰ïEƒƒfƒBƒAŒfÚ
 
ŽåÃŠw‰ïEŒ¤‹†‰ï
Šw‰ïŽQ‰Á—š—ð
Œ¤‹†ŽºˆõŽóÜ—š—ð
ƒƒfƒBƒAŒfÚî•ñ
sŽ–
•åW
ƒAƒNƒZƒX
 
’·è‘åŠwd“_‰Û‘èu’ɂݍŽ•ž‚̍‘Û“IŒ¤‹†‹³ˆç‹’“_‚ÌŒ`¬v
ŠÖ˜AƒŠƒ“ƒN
‚¨–â‚¢‡‚킹
XV—š—ð
 
 
Œ¤‹†‹ÆÑ
ƒz[ƒ€>Šw‰ïEŒ¤‹†‰ïEƒƒfƒBƒAŒfÚ>Šw‰ïŽQ‰Á—š—ð„ŠCŠOŠw‰ïEƒVƒ“ƒ|ƒWƒEƒ€u‰‰

ŠCŠOŠw‰ïEƒVƒ“ƒ|ƒWƒEƒ€u‰‰

“Á•Êu‰‰Aµ‘ҍu‰‰‚¨‚æ‚уVƒ“ƒ|ƒWƒEƒ€

  1. Takagi H, Satoh M, Shiomi H, Akaike A, Ueda H, Kawajiri S, Yamamoto M and AmanoH:Identification of a new opioid peptide from the bovine brain and its mechanism of action.International Narcotic Research Conference. June, 1979, Boston(USA)       
  2. Ueda HFEvidence for kappa-opioid receptor inhibition of G-protein activity in reconstitution experiments.nternational Narcotic Research Conference. Jun, 1992, Keystone, Denver(USA)
  3. Ueda HFSignal transduction of opioid, kyotorphin, nociceptin/orphanin FQ and sigma receptors.Symposium on Opioid Pharmacology. June 27, 1997, Chanju(Korea)
  4. Ueda HFIn vivo signal transduction in mice lacking receptor genes.
    International Narcotic Research Conference. July, 1998, Garmisch-Partenkirchen( Germany)
  5. Ueda H, Inoue MFIn vivo involvement of nociceptin in morphine-induced tolerance and dependence.The 8th Southeasr Asian-Western Pacific Regional Meeting of pharmacologists. Nov, 1999,‘ä–k(‘ä˜p)
  6. Ueda HFEnhanced spinal nociceptin system is involvd in thd development of morphine tolerance and dependence.International Narcotic Research Conference. July, 2000, Seattle (USA)
  7. Ueda HFDistinct roles of ppN/OFQ-derived peptides in pain control International Narcotic Research Conference. Jul, 2001, Helsinki( Finland)
  8. Ueda H: Locus-specific role of anti-opioid system in morphine tolerance and dependence.
    34th International Narcotic Research Conference Symposium (Adaptations to chronic opiates:from celllar events to in vivo responses), Jul, 2003, Perpignan (France)
  9. Ueda H: New approaches to visualize opioid tolerance and dependence.
    The 2004 European Opioid Conference, Apr, 2004, Visegrad(Hungary)
  10. Ueda H:Lysophosphatidic acid and neuropathic pain.
    The 2nd Asian Pain Symposium. Nov, 2004, Seoul(Korea)
  11. Ueda H:Locus-specific rescue of opioid receptor.37th International Narcotic Research Conference Symposium. Jul, 2006, St.Paul(USA)
  12. Ueda H: Molecular mechanisms of neuropathic pain - lysophosphatidic acid as the initiator.@The International Conference -Synapses-Memory-Drug Addiction-Pain-, Aug, 2006, Toronto(Canada)
  13. Ueda H: Molecular mechanisms underlying neuropathic pain - identification of related nociceptive fibers and the initiator, lysophosphatidic acid.The Study of Pain's Annual "Pain Day", Dec, 2006, Toronto(Canada)
  14. Ueda H: Molecular mechanisms of neuropathic pain.Opioids Past and Future: relevance to pain and addiction, Apr, 2007,Salamanca (Spain)
  15. Ueda H:Neural pathological roles for receptor mediated LPA signaling.FASEB@SUMMER@RESEARCH@CONFERENCE, Jun.2009,Arizona(USA)
  16. Ueda H:Identification of prothymosin alpha, the necrosis-apoptosis switch molecule in ischemic culture of cortical neuron. Second International Symposium on Thymosins in Health and Disease,Oct 2009,Catania(Italy)
  17. Ueda H: Epigenetic control of opioid receptor gene expression in neuropathic pain model,     INRC 2010,Malmo (Sweden)
  18. Ueda H:Rescue of specific promotor-regulated mu-opioid and nmda receptor gene into pag of k/o mice - pain species-specific brain loci for morphine analgesia and tolerance..IASP The 13th World Congress on Pain.2010,Montreal(Canada)
  19. Ueda H, Nagai J, Ma L, and Taira K:Feed-forward amplification of LPA3 receptor-mediated LPA production via microglia in the initiation of neuropathic pain.FASEB SUMMER@RESEARCH CONFERENCE- Lysophospholipid Mediators in Health & Disease.2011,Lucca(Italy)
  20. Ueda H, Nagai J, Lin Ma, Yano R, Shinohara K, Shinagawa A, and Taira K:PA receptor-mediated amplification of LPA biosynthesis and demyelination underlie the initiation mechanisms for neuropathic pain.The 9th IASP Research Symposium.2011.ãŠC(’†‘)
  21. Ueda H  Prothymosin ƒ¿: a novel neuroprotetive polypeptide against ischemic damages.2011 Taiwan-Japan Joint Symposium on Cell Signaling and Gene Regulation.2011‘ä–k(‘ä˜p)
  22. Ueda H: Prothymosin alpha: its mechanisms for non-vesucular release and receptor in central nervous system. THIRD INTERNATIONAL SYMPOSIUM ON THYMOSINS IN HEALTH AND DISEASE.2012, Washingtonl(USA).
  23. Ueda H:Epigenetic silencing of sodium channel, TRP channels and opioid receptor in neuropathic pain IASP 14‚”‚ˆ World Congress on Pain .2012.Milan(Italy)
  24. Ueda H:Repeated challenges of systemic mirtazapine cause permanent pain relief in mouse experimental fibromyalgia model. IASP 14‚”‚ˆ World Congress on Pain .2012.Milan,(Italy)
  25. Ueda H:Lysophosphatidic acid: Chemical signature of neuropathic pain.The 92nd Annual Meeting of the German Physiological Society.2013.Heidelberg(Germany )
  26. Ueda H, Nagai J, Mukae T, Matsushita Y :Blockade of lysophosphatidic acid receptor signaling completely cures the established chronic pain.13th Int1l Conference on BioactiveLipids in Cancer, Inflammation and Related Diseases.2013. San Juan(Puerto Ricoj
  27. Ueda H:My Phenotypic Switch Studies.CaltechNeuroimmunology Symposium.2014.Los Angeles(USA)
  28. Ueda H:Epigenetic mechanisms for pain: A novel approach to pain treatment  IASP 15th World Congress on Pain.2014. Buenos Aires(Argentine)
  29. Ueda H:Prothymosin alpha-derived Hexapeptide and i‚”s analogs ameliorate blood-brain barrier dysfunction following cerebral ischemia in mice.FOURTH INTERNATIONAL SYMPOSIUM ON THYMOSINS IN HEALTH AND DISEASE.2014.Roma(Italy)
  30. Ueda H:LPA as chemical signature of neuropathic pain mechanisms and therapeutic innovation.FASEB Science Research Conference.2015.Banff(Canada)
  31. Ueda H:Pharmacotherapeutic innovation against LPA-mediated chronic pain.14th International Conference .2015.BudapestiHungaryj
  32. Ueda H:Pharmacotherapeutic innovation using a novel experimental fibromyalgia model in mice.Pain Mechanisms and Therapeutics Conference.2016.Sicily( Italy)
  33. Ueda H:Lysophosphatidic acid: a biochemical signature for neuropathic pain.16th World Congress on Pain@iIASP).2016.Yokohama(Japan)
  34. Ueda H:Neuropathic pain initiation and maintenance: the role of glial°mediated LPA signaling in neuropathic pain models .16th World Congress on Pain@iIASP).2016.Yokohama(Japan)
  35. Ueda H:Brain Mechanisms and Pharmacotherapy in Generalized Chronic Pain Model Similar to Fibromyalgia in Mice.Fibromyalgia Research Symposium 2016 in Nagasaki(FRS 2016NAGASAKI).2016.Nagasaki(Japan)
  36. Ueda H:Fibromyalgia in mice.GLORIA symposium(glial-opioid-receptor-interface in analgesia symposium).2016.Strasbourg(France)
  37. Ueda H,Neyama H:Therapeutic recovery from diminished morphine analgesia in chronic pain state.The International Narcotics Research Conference 2017.2017.Chicago(USA)
  38. Ueda H,Neyama H:Brain mechanisms of LPA-signaling in the central pain.2017 FASEB .2017.New Orlean(USA)
 
’·è‘åŠw
 
Copyright